Outcomes of Staphylococcal Periprosthetic Joint Infections Treated With Rifampin and the Potential Role of Rifabutin as a Substitute When High-risk Drug-drug Interactions Exist
This study supports that rifampin as combination therapy with DAIR or one-stage revision in staphylococcal PJI leads to better outcomes; however, its implementation is limited by DDIs. [<i>Orthopedics</i>. 2025;48(4):239-247.].
Authors
- Rebekah Wrenn (ORCID: https://orcid.org/0000-0002-3394-3633)
- David N. Kugelman
- Sean P. Ryan (ORCID: https://orcid.org/0000-0003-4079-969X)
- A. Maćkowiak
- Thorsten M. Seyler (ORCID: https://orcid.org/0000-0003-1157-132X)
- Justin Leal (ORCID: https://orcid.org/0000-0001-5562-1005)
- William A. Jiranek (ORCID: https://orcid.org/0000-0001-9036-8674)
- Jessica Seidelman (ORCID: https://orcid.org/0000-0001-7117-513X)
- Sharrieff Shah (ORCID: https://orcid.org/0009-0003-1125-3679)
Institutions
- Rothman Orthopaedics (US)
- Rothman Institute (US)
- Duke University Hospital (US)
Publication Details
- Journal
- Orthopedics
- Published
- 2025-07-01
- DOI
- https://doi.org/10.3928/01477447-20250618-01
- Primary Topic
- Orthopedic Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00